IRBバルセロナとCNAGの研究チームが、転移性大腸がんが免疫療法を回避する二重バリアメカニズムを解明しNature Genetics誌に発表。TGF-βがT細胞の腫瘍侵入を阻止し、マクロファージにオステオポンチンを産生させてT細胞増殖を抑制。大腸がん患者の大多数を占めるMSS型への新治療法開発に期待。

A video from Nicholas Devito (as part of Duke Cancer Institute), posted on Oct 31, 2025.

Promega provides high-quality, CPD-accredited courses designed to support laboratory professionals in maintaining their certifications and advancing their knowledge in the latest developments in clinical and research settings. If you are looking to improve your understanding of molecular techniques, our courses are delivered by experts in the field to ensure you stay at the forefront of innovation.

Two of Moffitt’s patients are the first in the US to receive this treatment

The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) continued to demonstrate clinically meaningful progression-free survival (PFS) improvement over

Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.

In a phase 1b randomized clinical trial, Wang et al. demonstrate the additional benefit of dual immune checkpoint inhibition as neoadjuvant treatment for locally advanced MSI-H/dMMR colon cancer. Compared with sintilimab monotherapy, IBI310 (anti-CLTA-4) plus sintilimab significantly improved pathological complete response rate, without new safety signals.